Cancer Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>CG</div>
CGIX -- USA Stock  

USD 2.46  0.11  4.28%

In general, we focus on analyzing Cancer (NASDAQ:CGIX) price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cancer Genetics daily price indicators and compare them against related drivers. A current spike in volatility has left many investors looking confused. In this story, we will break down Cancer Genetics. We will look into a few reasons why it is still possible for the company to generate above-average margins and positive cash flow.
Published over three months ago
View all stories for Cancer Genetics | View All Stories
Should I hold on to my Cancer Genetics (NASDAQ:CGIX) position?
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cancer Genetics has an asset utilization ratio of 13.97 percent. This suggests that the company is making $0.14 for each dollar of assets. An increasing asset utilization means that Cancer Genetics is more efficient with each dollar of assets it utilizes for everyday operations.
The successful prediction of Cancer Genetics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Cancer Genetics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Cancer Genetics based on Cancer Genetics hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Cancer Genetics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Cancer Genetics's related companies.

Use Technical Analysis to project Cancer expected Price

Cancer Genetics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Cancer Genetics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Cancer Genetics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Cancer utilizes its cash?

To perform a cash flow analysis of Cancer Genetics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Cancer Genetics is receiving and how much cash it distributes out in a given period. The Cancer Genetics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Cancer Genetics Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Cancer Genetics reported Net Cash Flow from Operations of (8.66 Million) in 2019

Acquisition by Miles Michael Glenn of 10000 shares of Cancer Genetics subject to Rule 16b-3

Legal trades by Cancer Genetics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Cancer Genetics insider trading alert for grant of stock option (right to buy) by Miles Michael Glenn, Chief Financial Officer, on 28th of April 2020. This event was filed by Cancer Genetics Inc with SEC on 2020-04-28. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Cancer Genetics Investor Appetite?

The current indifference towards the small price fluctuations of Cancer Genetics could raise concerns from investors as the firm closed today at a share price of 2.84 on very low momentum in volume. The company management teams did not add any value to Cancer Genetics investors in July. However, most investors can still diversify their portfolios with Cancer Genetics to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently 5.05. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Cancer Genetics partners.
 2017 2018 2019 2020 (projected)
Revenues USD29.12 M4.93 M7.3 M10.39 M
Revenues29.12 M4.93 M7.3 M10.39 M

Deferred Revenue Breakdown

Cancer Genetics Deferred Revenue yearly trend continues to be fairly stable with very little volatility. Deferred Revenue is likely to outpace its year average in 2020. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Cancer Genetics Deferred Revenue is fairly stable at the moment as compared to the past year. Cancer Genetics reported Deferred Revenue of 1.22 Million in 2019
2010
2013
2014
2015
2016
2017
2018
2020
2010468,010
2013199,560
20141.47 Million
20151.58 Million
20161.22 Million
2017945,000
20181.21 Million
20201.24 Million

Our take on today Cancer Genetics slide

Current expected short fall indicator falls down to -4.52. Possible price jump? Cancer Genetics shows above-average downside volatility for the selected time horizon. We advise investors to inspect Cancer Genetics further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Cancer Genetics future alpha.

Our Final Takeaway

While some firms in the biotechnology industry are either recovering or due for a correction, Cancer Genetics may not be performing as strong as the other in terms of long-term growth potentials. All things considered, as of the 24th of August 2020, we believe Cancer Genetics is currently overvalued. It barely shadows the market and projects quite high probability of financial unrest in the next two years. Our primary 30 days 'Buy-vs-Sell' recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Cancer Genetics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com